000			01387 a2200349 4500
005			20250516051210.0
264		0	_c20111207
008			201112s 0 0 eng d
022			_a1179-190X
024	7		_a10.2165/11207100-000000000-00000 _2doi
040			_aNLM _beng _cNLM
100	1		_aMoen, Marit D
245	0	0	_aSpotlight on denosumab in postmenopausal osteoporosis. _h[electronic resource]
260			_bBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy _cAug 2011
300			_a261-4 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAntibodies, Monoclonal _xeconomics
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aBone Density _xdrug effects
650	0	4	_aClinical Trials, Phase II as Topic
650	0	4	_aClinical Trials, Phase III as Topic
650	0	4	_aDenosumab
650	0	4	_aFemale
650	0	4	_aFractures, Bone _xdrug therapy
650	0	4	_aHumans
650	0	4	_aOsteoporosis, Postmenopausal _xdrug therapy
650	0	4	_aRANK Ligand _xeconomics
650	0	4	_aRandomized Controlled Trials as Topic
700	1		_aKeam, Susan J
773	0		_tBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy _gvol. 25 _gno. 4 _gp. 261-4
856	4	0	_uhttps://doi.org/10.2165/11207100-000000000-00000 _zAvailable from publisher's website
999			_c21060824 _d21060824